ABSTRACT
. Anti-tumor necrosis factor (anti-TNF) drugs are recommended as therapy for patients with high disease activity despite the first-line treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) [3] . Randomized clinical trials and observational studies have shown that patients treated with anti-TNF agents experience a decrease in disease activity and better functionality [4] . The National Register for Biologic Treatment in Finland (ROB-FIN) reported that 52% of patients receiving anti-TNF therapy achieved 50% improvement on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) after 6 months [5] ;
the British Society for Rheumatology Biologics Register reported a very similar outcome in 50% of patients [6] .
Evaluations on the impact of long-term use of these drugs in real life settings are required because the impact of anti-TNF therapy on patients may differ from that seen in clinical trials, which usually have short follow-up periods and selection criteria that restrict patients with comorbidities and concomitant drugs. The Brazilian Registration of Spondyloarthritis and the Brazilian Biologic Registry (BIOBADA BRASIL) collects epidemiological and clinical data on the exposure of patients to anti-TNF drugs [7, 8] .
However, little is known to date on the effectiveness and quality-of-life outcomes in Brazilian AS patients receiving anti-TNF therapy.
The BIOBADA BRASIL estimated that 400 patients with AS started anti-TNF therapy in 2009 [7] . In 2010, the Brazilian National Health Questionnaire-Disability Index (HAQ) [11, 12] and by the EuroQol-5D (EQ-5D), respectively.
The generic EQ-5D questionnaire includes five dimensions of health addressing mobility, self-care, usual activities, pain/discomfort and anxiety/depression and provides a summary of health utility scores derived from a study performed in Minas Gerais state (Belo Horizonte is the capital of Minas Gerais state) [13] . It also contains a vertical VAS ranging from 0 (worst imaginable health state) to 100 (best imaginable health state) [14] . Episodes of adverse events were also recorded.
We calculated the frequency distributions for categorical variables and the median and interquartile range (IQR) for continuous variables. In addition to determining the overall BASDAI score, we described its components separately: fatigue, spinal pain, pain and swelling peripheral joints, enthesitis, and duration of morning stiffness. We compared baseline assessments among patients with a baseline BASDAI C4 and BASDAI \4 and applied Student's t test when the values were normally distributed and the Mann-Whitney test otherwise. We compared clinical outcomes at baseline and at 6 and 12 months of follow-up and applied the paired Student's t test when the results were normally distributed and the Wilcoxon signed rank sum test otherwise.
Logistic regression and odds ratio (OR) with 95% confidence interval (95% CI) were used to identify predictor factors associated with good clinical response at 6 months. The duration of disease, baseline PtGA, HAQ, EQ-5D, EQ-5D VAS, fatigue, spinal pain, pain and swelling peripheral joints, enthesitis and duration of morning stiffness were included as continuous variables, whereas age (quartiles), gender, education, race, type of anti-TNF therapy, baseline use of NSAIDs, disease-modifying antirheumatic drugs (DMARDs) and corticosteroid were included as categorical variables. Only statistically significant variables were retained in the final model by the stepwise-backward method. We adopted a significance level of 5%, and the statistical analyzes were performed using SAS version 9.4 for UNIX (SAS Institute Inc., Cary, NC). 
Compliance with Ethics Guidelines

RESULTS
Our initial survey identified 98 patients with AS who had received therapy with the anti-TNF agents infliximab, etanercept or adalimumab and initiated follow-up during the study period.
Of these, 11 had a prior history of anti-TNF therapy and were excluded from entry. The final patient cohort therefore included 87 patients, of whom 63 and 32 completed 6 and 12 months of follow-up, respectively. The reason for withdraw was not addressed. The characteristics of the study participants are presented in Table 1 . Most patients were male (63.3%), the median age was 41.0 (IQR 31.9-51.3) years and the median disease corticosteroids, 35.6% were using NSAIDs and 27.6% were using DMARDs (mainly methotrexate); during the follow-up, the frequency of concomitant therapy dropped (Table 2) .
At baseline, 64 (73.6%) patients had a BASDAI score of C4. Compared to patients with a BASDAI score of \4, these patients had a longer disease duration (p = 0.0266; Table 1 ), worse assessment on the PtGA, HAQ and EQ-5D (p\0.0005), and similar EQ-5D VAS (p = 0.1700) (data not shown). Among patients with a baseline BASDAI score of C4, 63.1 and 64.7% achieved a BASDAI score of \4 at 6 and 12 months, respectively. (Table 4) .
At the end of the study, 93 adverse events had been reported by 56 (57.1%) patients, with the most common being headache (16.1%), influenza (14.1%) and application site reaction (14.0%). A number of cases of infection were (Table 5) .
DISCUSSION
This is the first study to evaluate patients with AS who were treated with anti-TNF through the assistance of a public drug program in Brazil.
Our study followed-up patients who were diagnosed with AS according to the Brazilian Therapeutic Guideline and treated with anti-TNF drugs in the city of Belo Horizonte.
All patients enrolled in the study were from a real-life clinical setting. Our findings showed an the BASDAI up to 6 months of therapy and that the BASDAI score fell from a median baseline value of 5.9 to a median value of 2.6 at 6 months, and then to 21 at 12 months. A clinical response was also observed for BASFI, Bath Ankylosing Spondylitis Metrology Index (BASMI), pain and fatigue and was sustained more than 5 years [15] . Other studies have evaluated the HRQoL using the Short Form 36
(SF36) and found clinical improvement after 4 and 6 months of etanercept and infliximab therapy [16, 17] .
In our patient cohort, male gender was a good predictor of clinical response. Another
Brazilian study involving patients with spondyloarthritis reported that female gender was associated with more painful and swollen joints and higher BASDAI and BASFI scores [18] . An Italian study found that male AS patients had higher chances of achieving a partial remission response after 12 months of anti-TNF therapy than female AS patients (OR 2.05, 95% CI 1.09-3.84), but that after 24 months the difference was not significant (OR 1.30, 95% CI 0.60-3.04) [19] . In contrast, the Danish Registry found a non-significant association with gender [15] . Fibromyalgia affects 15% of AS patients in a male:female ratio of 1:3, and its symptoms of morning stiffness, fatigue and pain can lead to a confounding effect in the disease activity response, whereas the variables of anti-TNF drug and disease duration did not reach statistical significance [6, 15] .
In our study, 36.8% of patients were using corticosteroids on baseline and 26.9% were still using corticosteroids after 12 months of follow-up, probably to treat peripheral or extra-articular manifestations, since the use of corticosteroids for axial disease is not supported by current evidence [3, 22] . However, we could not confirm this supposition because we did not address the reasons for corticosteroid use in our study. The frequency of corticosteroid use among patients with AS has been found to be lower in other studies, ranging from 15 to 30% at the start anti-TNF therapy [5, 6] . Thus, our results should raise awareness of the potential for the irrational prescribing and use of these drugs given the risks associated with their chronic use.
The anti-TNF therapy was well tolerated, with patients reporting primarily minor adverse events and few infections. The BIOBADA BRASIL reported that one-third of AS patients discontinued therapy due to adverse effects [23], and Glintborg et al. [15] reported a similar rate among Danish patients. Conversely, other studies have reported that adverse events were the major reason for drug discontinuation [24, 25] .
In our study, one-fourth of patients had a baseline BASDAI score of \4, which means that they did not meet the inclusion criteria of the Brazilian Therapeutic Guideline to start anti-TNF therapy [10] . This may indicate that there is a trend in Brazil towards initiating One limitation of our study relates to the method applied to contact the patients. Only those who visited the specified pharmacies were eligible to participate in the study and to be followed-up at 6 and 12 months. The drug can be dispensed for a family member if the patient is not able to attend the pharmacy; thus, patients with severe AS may not have been included in the study and/or may have withdrawn during the follow-up, which could have biased the number of reports of serious adverse events. Throughout the study period, the waiting time for medication dispensing at the pharmacies became shorter due to improvements in organization. As patients were frequently assessed while they were waiting for their medication dispensing, the better organization may have resulted in fewer patients being willing to be interviewed. This potential for decrease in the number of patients being interviewed together with the commonly known reasons of therapy discontinuation, such as loss of efficacy and adverse events, could have contributed to the high withdraw rate observed at the 12-month follow-up [15, 18] . Other studies have shown that the 1-year anti-TNF drug survival can range between 70% and 83% among AS patients [27, 28] .
The lack of access to the clinical data for a number of patients is also a limiting factor in our study. These patients had the diagnosis of AS confirmed by their physician in accordance with the criteria of the Brazilian Therapeutic Guideline, but additional information on their clinical status was unavailable. We also were unable to determine the motivation underlying the initiation of anti-TNF therapy in patients with a BASDAI score of \4. In addition, laboratory indices, such as CRP, ESR and positivity for HLA-B27, were not assessed in our study.
CONCLUSION
Our results show that anti-TNF therapy is very effective in treating AS and that it is well tolerated among patients enrolled in our study. 
